Pharmaceuticals

Global First Engineered Exosome with INCI Name -- ImmVira Leads a New Era in International Cosmetic Ingredients

SUZHOU, China, April 10, 2025 /PRNewswire/ -- EonveLab, a subsidiary of ImmVira Group ("ImmVira," or the "Company"), recently announced that its in-house developed engineered exosome product, MVR-EX103, developed for treating superficial skin depressions, has successfully passed the review of th...

2025-04-11 13:19 4570

Florida Theranostics Brings Cutting-Edge United Imaging Digital PET/CT to Palm Beach County, Florida

The uMI Panorama™ from United Imaging is the first in Florida. HOUSTON, April 10, 2025 /PRNewswire/ -- United Imaging, a global manufacturer of modern medical imaging technology, will feature its uMI Panorama at a state-of-the-art new facility inJupiter, FL. Focused on patient-centered and preci...

2025-04-11 00:27 2825

Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer

CAMBRIDGE, Mass., April 10, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), ranging from target validation and antibody discovery through preclinical research, today announced a research collaboration with Atossa ...

2025-04-10 20:00 2873

Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China's first hemophilia B gene therapy, was officially approved

SHANGHAI, April 10, 2025 /PRNewswire/ -- Belief BioMed ("BBM") and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the National Medical Products Administration (NMPA) for the treatment of adult patients with mod...

2025-04-10 19:23 8037

Medtec Southeast Asia 2025 - The Southeast Asia's Premier Medical Device Design & Manufacturing Exhibition Debuts in Malaysia

KUALA LUMPUR, Malaysia, April 10, 2025 /PRNewswire/ -- Informa Markets announces the launch ofMedtec Southeast Asia 2025, the premier medical device design and manufacturing exhibition inSoutheast Asia, making its debut in Malaysia. The inaugural Medtec Southeast Asia 2025 exhibition will take p...

2025-04-10 16:58 6379

Seegene Announces Development of CURECA™, a Next-Generation Fully Automated PCR Solution Featuring Customizable Pre-treatment Automation

- Seegene to showcase a conceptual video introducing CURECA™ at ESCMID Global 2025 — a full automation systemexpected to cover the entire PCR workforce, from sample pre-processing to result analysis. - Designed for 24-hour, seven-days-a-week, unattended, CURECA™ reflects the company's mission to ...

2025-04-09 21:00 4812

Ractigen's RAG-17 ALS Data Shines at AAN 2025: Earns Top Award, Phase I Advances

* Final results from an Investigator-Initiated Trial presented for the first time, demonstrating favorable safety, significant target engagement, and encouraging clinical & biomarker signals * Abstract honored with prestigious "Abstracts of Distinction" award by AAN Science Committee, recogni...

2025-04-09 20:00 5485

Darnatein, an OSR Company, Broadens Intellectual Property Protection for Innovative Osteoarthritis Treatment Technology

SEOUL, South Korea, April 9, 2025 /PRNewswire/ -- Darnatein, a wholly-owned subsidiary of OSR Holdings, Inc. (NASDAQ: OSRH), today announces that it has successfully secured an additional international patent for its protein-based osteoarthritis treatment technology, marking a significant step in...

2025-04-09 19:54 3391

Asia Health & Medlab Asia Rebrands to WHX and WHX Labs in Kuala Lumpur and Bangkok

KUALA LUMPUR, Malaysia, April 9, 2025 /PRNewswire/ -- The global event organisation leader Informa Markets revealed a major rebranding of its healthcare exhibitions portfolio which resulted in the formation of WHX (World Health Expo). WHX rebrands its healthcare events acrossSoutheast Asia to WHX...

2025-04-09 19:49 5499

GC Biopharma Receives MFDS Approval for World's First Recombinant Anthrax Vaccine

YONGIN, South Korea, April 9, 2025 /PRNewswire/ -- GC Biopharma announced 09. Apr. 2025 that the Korean Ministry of Food and Drug Safety (MFDS) has approved its anthrax vaccine, BARYTHRAX, jointly developed by GC Biopharma and the Korea Disease Control and Prevention Agency (KDCA). With the ap...

2025-04-09 12:00 3154

Alpro Pharmacy Now Offers Free AIA Vitality Health Check to Support Early Disease Detection

KUALA LUMPUR, Malaysia, April 9, 2025 /PRNewswire/ -- Millions of Malaysians are at risk of serious health complications due to undiagnosed and unmanaged non-communicable diseases (NCDs), such as diabetes, hypertension, high cholesterol, and obesity. According to the National Health and Morbidity...

2025-04-09 10:00 3531

MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025

SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clin...

2025-04-08 15:38 4396

Engine Biosciences and Experimental Drug Development Centre Partner to Advance Novel Therapies to Combat Cancer

* This marks the first-ever collaboration between Engine Biosciences and Experimental Drug Development Centre (EDDC),Singapore's national platform for drug discovery and development. * The partnership will advance the development of first-in-class precision therapeutics for multiple cancer ty...

2025-04-08 09:00 3113

Duality Bio Appoints Hua Mu as Global Chief Medical Officer

SHANGHAI, April 7, 2025 /PRNewswire/ -- DualityBio announced today that Dr. Hua Mu has joined the company as Global Chief Medical Officer (CMO). In this role, Dr. Mu will oversee the strategic planning, meticulous design, efficient execution, and comprehensive regulatory compliance of the company...

2025-04-07 12:52 3657

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectivelydeliver molecules across the blood-brain barrier - ABL Bio to receive up to £77 million in upfront and n...

2025-04-07 08:34 6017

George Clinical Rebrands as Emerald Clinical Trials

New name reflects company's growth and vision to help bring certainty and transparency to global clinical trials SINGAPORE, April 7, 2025 /PRNewswire/ -- George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to becomeEmerald ...

2025-04-07 08:00 3777

Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., April 6, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with schizophrenia and as a monotherapy or adjunct therapy fo...

2025-04-07 08:00 3302

Telix Appoints Paul Schaffer as Chief Technology Officer

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that is has appointed Dr.Paul Schaffer to the newly created role of Chief Technology Officer (CTO), effective today.   Dr. Schaffer has...

2025-04-07 07:09 4647

The Phase III Study Data of Stapokibart for Seasonal Allergic Rhinitis Published in Nature Medicine

CHENGDU, China, April 5, 2025 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced that the prestigious medical journalNature Medicine has published the results from the Phase III trial of its independently developed IL-4Rα antibody stapokibart, for th...

2025-04-06 10:12 4262

China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

HAIKOU, China, April 4, 2025 /PRNewswire/ -- China Pharma Holdings Inc. ("China Pharma" or the "Company") (NYSE American: CPHI) reported that it expects to implement a 1-for-10 reverse stock split on its common stock effectiveTuesday, April 15, 2025, with trading to begin on a split-adjusted basi...

2025-04-05 04:05 7457
1 ... 87888990919293 ... 345